ARK Invest Increases Stake in CRISPR Therapeutics Amid Market Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CRSP?
Source: seekingalpha
- Increased Stake in Gene Editing: ARK Invest purchased 280,609 shares of CRISPR Therapeutics (NASDAQ:CRSP) worth approximately $14.82 million, following a 10% drop in the stock due to a $350 million private offering, indicating confidence in the company's long-term potential.
- Portfolio Rebalancing Strategy: Concurrently, ARK trimmed positions in related firms, offloading 78,412 shares of 10x Genomics (TXG) for about $1.60 million and 21,505 shares of Teradyne (TER) for $6.47 million, reflecting its rebalancing strategy across actively managed ETFs.
- Portfolio Weighting: CRISPR Therapeutics is the second-largest holding in ARK's ETFs, with a portfolio weight of 4.49% and total exposure of around $500 million, underscoring the company's significance and growth opportunities within ARK's investment strategy.
- Market Analysis Ratings: CRISPR Therapeutics has received a 'Buy' rating from Seeking Alpha due to its strong cash position and high growth potential, despite significant risks, with Wall Street analysts also rating the stock as 'Buy', indicating optimistic market expectations for its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 58.780
Low
50.00
Averages
78.89
High
105.00
Current: 58.780
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics Prices $550M Convertible Notes Offering
- Increased Financing Size: CRISPR Therapeutics upsized its planned $350M convertible notes offering to $550M, reflecting strong market demand and providing the company with enhanced financial resources for future initiatives.
- Additional Purchase Option: Buyers have the option to purchase an additional $50M of notes within 13 days of issuance, which not only increases investor engagement but also has the potential to further boost the total financing amount for the company.
- Interest Rate and Conversion Terms: The notes carry an effective coupon of 1.125%, with an initial conversion price of approximately $76.56 per share, representing a 45% premium over the last reported price, indicating the company's confidence in future stock performance while offering investors potential capital appreciation.
- Clear Use of Proceeds: The company expects to raise about $536.3M in net proceeds from the offering, or $585.2M if the additional purchase option is fully exercised, with funds allocated for general corporate purposes to support strategic growth and operational needs.
See More
ARK Invest Increases Stake in CRISPR Therapeutics Amid Market Volatility
- Increased Stake in Gene Editing: ARK Invest purchased 280,609 shares of CRISPR Therapeutics (NASDAQ:CRSP) worth approximately $14.82 million, following a 10% drop in the stock due to a $350 million private offering, indicating confidence in the company's long-term potential.
- Portfolio Rebalancing Strategy: Concurrently, ARK trimmed positions in related firms, offloading 78,412 shares of 10x Genomics (TXG) for about $1.60 million and 21,505 shares of Teradyne (TER) for $6.47 million, reflecting its rebalancing strategy across actively managed ETFs.
- Portfolio Weighting: CRISPR Therapeutics is the second-largest holding in ARK's ETFs, with a portfolio weight of 4.49% and total exposure of around $500 million, underscoring the company's significance and growth opportunities within ARK's investment strategy.
- Market Analysis Ratings: CRISPR Therapeutics has received a 'Buy' rating from Seeking Alpha due to its strong cash position and high growth potential, despite significant risks, with Wall Street analysts also rating the stock as 'Buy', indicating optimistic market expectations for its future performance.
See More
Three Stocks Poised for Decade-Long Gains
- High Growth Potential: Qualcomm (QCOM) is positioned to lead the AI edge computing market, projected to grow at an annual rate of 32% through 2029, enhancing its competitive edge by applying AI technology to automotive and industrial automation.
- E-commerce Market Opportunity: MercadoLibre (MELI) continues to expand its share in the Latin American e-commerce market, with last year's revenue growth of 44% and 39% year-over-year, despite profit pressures from free shipping initiatives, indicating strong market demand.
- Gene Therapy Breakthrough: CRISPR Therapeutics (CRSP) received FDA approval for its gene therapy Casgevy, with expectations of generating over $500 million in revenue through its partnership with Vertex Pharmaceuticals by 2026, marking a significant recognition of gene therapies in the pharmaceutical industry.
- Long-term Investment Strategy: Despite recent stock performance challenges for all three companies due to short-term pressures, their long-term growth potential and market share expansion strategies are set to lay the groundwork for future investment returns.
See More
CRISPR Therapeutics' Financing Plan Triggers Stock Price Drop
- Financing Impact: CRISPR Therapeutics announced plans to sell $350 million in convertible notes to raise funds, resulting in a stock price drop of over 12%, reflecting market concerns about potential dilution of existing shareholders' stakes.
- Market Reaction: As of 3:21 p.m. ET Tuesday, CRISPR's stock price stood at $52.51 with a market cap of $5.6 billion, indicating a cautious investor sentiment towards the financing needs of biotech startups.
- Financial Condition: At the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but total liabilities were $343.4 million, including $149 million in current liabilities, highlighting a tight financial management situation.
- Future Outlook: Despite the financing news causing a short-term stock decline, analysts have set a price target of $81.21 for CRISPR, suggesting a continued optimistic view on its long-term potential, especially with ongoing advancements in gene therapy.
See More
CRISPR Therapeutics Issues Debt to Advance Drug Portfolio
- Debt Issuance Plan: CRISPR Therapeutics announced its intention to issue $350 million in convertible notes for 'general corporate purposes,' a move that may dilute existing shareholders' stakes and reflects the company's tight funding situation.
- Market Reaction: Following this announcement, CRISPR's stock price fell over 12% on Tuesday, indicating investor concerns about the company's future financial health, especially given its total liabilities of $343.4 million.
- Cash Flow Status: As of the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but burned through $345 million last year on drug development, highlighting the high-risk nature of its funding usage.
- Clinical Trial Progress: Despite facing short-term challenges, CRISPR is conducting five clinical trials, and its analysts' consensus price target of $81.21 suggests ongoing market confidence in its long-term potential, presenting an opportunity for investors to consider entry.
See More
CRISPR Therapeutics to Issue $350 Million Convertible Notes
- Convertible Note Offering: CRISPR Therapeutics plans to issue $350 million in convertible senior notes due in 2031 through a private placement aimed at qualified institutional investors, which is expected to enhance the company's capital structure and liquidity.
- Bond Terms Details: Under Rule 144A of the Securities Act, the notes will rank as senior unsecured obligations, with interest payments occurring biannually, starting in September 2026, providing a stable cash inflow to support ongoing R&D activities.
- Use of Proceeds: While management did not specify particular spending priorities, the proceeds are expected to be allocated toward general corporate purposes, potentially including further development of gene-editing therapies targeting blood disorders and oncology.
- Recent Earnings Performance: The company's latest gene-editing therapy, Casgevy, generated $54 million in revenue for the fourth quarter and $116 million for the full year, indicating strong market potential and demand for its products, despite an 8.54% drop in stock price at the time of publication.
See More
CRISPR Therapeutics Prices $550M Convertible Notes Offering
- Increased Financing Size: CRISPR Therapeutics upsized its planned $350M convertible notes offering to $550M, reflecting strong market demand and providing the company with enhanced financial resources for future initiatives.
- Additional Purchase Option: Buyers have the option to purchase an additional $50M of notes within 13 days of issuance, which not only increases investor engagement but also has the potential to further boost the total financing amount for the company.
- Interest Rate and Conversion Terms: The notes carry an effective coupon of 1.125%, with an initial conversion price of approximately $76.56 per share, representing a 45% premium over the last reported price, indicating the company's confidence in future stock performance while offering investors potential capital appreciation.
- Clear Use of Proceeds: The company expects to raise about $536.3M in net proceeds from the offering, or $585.2M if the additional purchase option is fully exercised, with funds allocated for general corporate purposes to support strategic growth and operational needs.
See More
ARK Invest Increases Stake in CRISPR Therapeutics Amid Market Volatility
- Increased Stake in Gene Editing: ARK Invest purchased 280,609 shares of CRISPR Therapeutics (NASDAQ:CRSP) worth approximately $14.82 million, following a 10% drop in the stock due to a $350 million private offering, indicating confidence in the company's long-term potential.
- Portfolio Rebalancing Strategy: Concurrently, ARK trimmed positions in related firms, offloading 78,412 shares of 10x Genomics (TXG) for about $1.60 million and 21,505 shares of Teradyne (TER) for $6.47 million, reflecting its rebalancing strategy across actively managed ETFs.
- Portfolio Weighting: CRISPR Therapeutics is the second-largest holding in ARK's ETFs, with a portfolio weight of 4.49% and total exposure of around $500 million, underscoring the company's significance and growth opportunities within ARK's investment strategy.
- Market Analysis Ratings: CRISPR Therapeutics has received a 'Buy' rating from Seeking Alpha due to its strong cash position and high growth potential, despite significant risks, with Wall Street analysts also rating the stock as 'Buy', indicating optimistic market expectations for its future performance.
See More
Three Stocks Poised for Decade-Long Gains
- High Growth Potential: Qualcomm (QCOM) is positioned to lead the AI edge computing market, projected to grow at an annual rate of 32% through 2029, enhancing its competitive edge by applying AI technology to automotive and industrial automation.
- E-commerce Market Opportunity: MercadoLibre (MELI) continues to expand its share in the Latin American e-commerce market, with last year's revenue growth of 44% and 39% year-over-year, despite profit pressures from free shipping initiatives, indicating strong market demand.
- Gene Therapy Breakthrough: CRISPR Therapeutics (CRSP) received FDA approval for its gene therapy Casgevy, with expectations of generating over $500 million in revenue through its partnership with Vertex Pharmaceuticals by 2026, marking a significant recognition of gene therapies in the pharmaceutical industry.
- Long-term Investment Strategy: Despite recent stock performance challenges for all three companies due to short-term pressures, their long-term growth potential and market share expansion strategies are set to lay the groundwork for future investment returns.
See More
CRISPR Therapeutics' Financing Plan Triggers Stock Price Drop
- Financing Impact: CRISPR Therapeutics announced plans to sell $350 million in convertible notes to raise funds, resulting in a stock price drop of over 12%, reflecting market concerns about potential dilution of existing shareholders' stakes.
- Market Reaction: As of 3:21 p.m. ET Tuesday, CRISPR's stock price stood at $52.51 with a market cap of $5.6 billion, indicating a cautious investor sentiment towards the financing needs of biotech startups.
- Financial Condition: At the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but total liabilities were $343.4 million, including $149 million in current liabilities, highlighting a tight financial management situation.
- Future Outlook: Despite the financing news causing a short-term stock decline, analysts have set a price target of $81.21 for CRISPR, suggesting a continued optimistic view on its long-term potential, especially with ongoing advancements in gene therapy.
See More
CRISPR Therapeutics Issues Debt to Advance Drug Portfolio
- Debt Issuance Plan: CRISPR Therapeutics announced its intention to issue $350 million in convertible notes for 'general corporate purposes,' a move that may dilute existing shareholders' stakes and reflects the company's tight funding situation.
- Market Reaction: Following this announcement, CRISPR's stock price fell over 12% on Tuesday, indicating investor concerns about the company's future financial health, especially given its total liabilities of $343.4 million.
- Cash Flow Status: As of the end of last year, CRISPR had $347.6 million in cash and cash equivalents, but burned through $345 million last year on drug development, highlighting the high-risk nature of its funding usage.
- Clinical Trial Progress: Despite facing short-term challenges, CRISPR is conducting five clinical trials, and its analysts' consensus price target of $81.21 suggests ongoing market confidence in its long-term potential, presenting an opportunity for investors to consider entry.
See More
CRISPR Therapeutics to Issue $350 Million Convertible Notes
- Convertible Note Offering: CRISPR Therapeutics plans to issue $350 million in convertible senior notes due in 2031 through a private placement aimed at qualified institutional investors, which is expected to enhance the company's capital structure and liquidity.
- Bond Terms Details: Under Rule 144A of the Securities Act, the notes will rank as senior unsecured obligations, with interest payments occurring biannually, starting in September 2026, providing a stable cash inflow to support ongoing R&D activities.
- Use of Proceeds: While management did not specify particular spending priorities, the proceeds are expected to be allocated toward general corporate purposes, potentially including further development of gene-editing therapies targeting blood disorders and oncology.
- Recent Earnings Performance: The company's latest gene-editing therapy, Casgevy, generated $54 million in revenue for the fourth quarter and $116 million for the full year, indicating strong market potential and demand for its products, despite an 8.54% drop in stock price at the time of publication.
See More
